Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose
The influx of multiple generic variants within days of patent expiry has led to widespread availability across retail pharmacies, online platforms, and wellness clinics, often without adequate regulatory compliance
The molecular synergy occurs at multiple levels
Patients with obesity and type 2 diabetes often face a dual burden of hyperuricemia and gout, yet these conditions are not always addressed in treatment plans
In its decision to deem the shortage resolved, the FDA considered the manufacturers production capabilities and existing inventory, in addition to wholesaler inventory
Similar investigations have been performed for subcutaneous treatment with tirzepatide, a combined glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist [29], as well as for the GLP-1RAs liraglutide, exenatide, dulaglutide, and semaglutide [30,31,32,33,34]